Af­ter dis­ap­point­ing Wall Street last year, De­nali touts new bio­mark­er da­ta hop­ing to forge clear path to FDA

Look­ing to build out a case for its drugs that can bet­ter pen­e­trate the blood-brain bar­ri­er, De­nali Ther­a­peu­tics tout­ed new in­ter­im Hunter syn­drome da­ta Wednes­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER